Amicus Therapeutics, Inc. FOLD was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $12.85–$15.67 in the past one-month time frame, witnessed a sharp increase yesterday.
The move came after the company provided encouraging full-year 2018 strategic outlook and financial guidance.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Amicus Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. Price | Amicus Therapeutics, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Exelixis, Inc. EXEL, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is FOLD going up? Or down? Predict to see what others think:Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research